Assess Genetic Risk for Opioid Addiction with AvertD

When it comes to treating acute pain―pain expected to last less than 30 days―prescription opioids may be effective, but they also come with a risk of addiction. Because that risk is higher for some people than others, it’s critical that physicians understand their patients’ personal risk for addiction before opioids are ever prescribed. AvertD™ is a genetics-based risk assessment that supports more informed decision-making when a first prescription of oral opioids for acute pain is being considered.

Assess Genetic Risk for Opioid Addiction with AvertD

When it comes to treating acute pain―pain expected to last less than 30 days―prescription opioids may be effective, but they also come with a risk of addiction. Because that risk is higher for some people than others, it’s critical that physicians understand their patients’ personal risk for addiction before opioids are ever prescribed. AvertD™ is a genetics-based risk assessment that supports more informed decision-making when a first prescription of oral opioids for acute pain is being considered.

providers.affordable

Who Is At Increased Genetic
Risk for Opioid Addiction?

There are many entry points for opioid misuse and addiction, which can impact anyone. For some people, their first exposure to opioids is when they receive a prescription from their doctor to treat acute pain, often following surgery or an injury. It’s important to understand that everyone who takes prescription opioids is at risk for addiction, but some people are at higher risk than others.

When use of prescription opioids for acute pain is being considered, risk assessment is a widely recommended step in the decision-making process. There are many known factors associated with increased risk for Opioid Use Disorder (OUD), but genetics is one of the most significant.1 With AvertD, physicians and their patients now have a way to assess genetic risk for OUD before a prescription is written.

1Bevilacqua L, Goldman D. Genes and addictions. Clin Pharmacol Ther. 2009; 85(4):359–361. doi:10.1038/clpt.2009.6
privacy-for-patients-mobile

Know the Risk for Opioid Addiction Now, Not Later

AvertD is a clinically validated genetic test that analyzes 15 genetic markers involved in the brain reward pathways associated with addiction to identify if a patient may be at increased genetic risk for developing Opioid Use Disorder (OUD). When a first prescription of oral opioids is being considered to treat acute pain, AvertD provides personalized genetic risk information to physicians and their patients, which can be used to help tailor their pain management plan accordingly.

NOTE: Because genetics are only one factor in understanding the risk of developing OUD from using oral opioids, AvertD test results should always be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in an acute pain management plan.

Know the Risk for Opioid
Addiction Now, Not Later

AvertD is a clinically validated genetic test that analyzes 15 genetic markers involved in the brain reward pathways associated with addiction to identify if a patient may be at increased genetic risk for developing Opioid Use Disorder (OUD). When a first prescription of oral opioids is being considered to treat acute pain, AvertD provides personalized genetic risk information to physicians and their patients, which can be used to help tailor their pain management plan accordingly.

NOTE: Because genetics are only one factor in understanding the risk of developing OUD from using oral opioids, AvertD test results should always be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in an acute pain management plan.

privacy-for-patients-mobile
Opioid Crisis

How Genetic Risk Assessment
for Opioid Addiction Works

AvertD is a physician-ordered test that requires only a simple cheek swab sample. The sample is then mailed to our CLIA-certified, CAP-accredited lab for analysis. After the sample has been processed, a results report identifying the patient as having either a High or Low Genetic Risk is delivered to the ordering healthcare provider via a secure online portal. The provider then discusses the results with the patient so they can decide together how to best manage their acute pain.

Learn More About AvertD

I am a patient interested in learning more about AvertD for myself or a loved one.

I am a healthcare provider interested in offering AvertD at my practice to patients.

Read Our Latest Blog

Could Opioid Addiction Impact You?

Could Opioid Addiction Impact You?

For some people, their first exposure to opioids is when they receive a prescription from their doctor to treat acute pain following surgery or an injury. Unfortunately, most people don’t know their risk for addiction before an opioid is prescribed to them.

read more